KR Mali, M Eerike, GM Raj, D Bisoi… - Irish Journal of Medical …, 2023 - Springer
… Authorization in three countries for the treatment of mildCOVID-19. The aim of this systematic review was to find out the safety and efficacy of Molnupiravir in SARS-COV-2 infections. …
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2021 - Elsevier
… and safety of molnupiravir in patients with COVID-19. … Molnupiravir is first oral antiviral drug to demonstrate a significant benefit in reducing hospitalization or death in mildCOVID-19 and …
SK Tippabhotla, DS Lahiri, C Kandi - 2022 - papers.ssrn.com
… of COVID-19. This study evaluates the efficacy and safety of molnupiravir in addition to … standard-of-care (SOC) for the treatment of non-hospitalized patients with mildCOVID-19. …
Y Gao, M Liu, Z Li, J Xu, J Zhang, J Tian - Clinical Microbiology and …, 2023 - Elsevier
… assess the efficacy and safety of molnupiravir in patients with mild or moderate COVID-19. … thus far of the efficacy and safety of molnupiravir in treating patients with mild to moderate …
…, G Castaldo, AR Buonomo, Federico Ii Covid Team - Vaccines, 2022 - mdpi.com
… Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against … on the efficacy and safety of OAs during the omicron surge of the COVID-19 pandemic. Among …
… of molnupiravir among mild or moderate COVID-19 patients. … for relevant records were “Molnupiravir,” “COVID-19,” and “… of molnupiravir with a placebo for COVID-19 treatment. The …
JJ Malin, S Weibel, H Gruell… - Journal of …, 2023 - academic.oup.com
… Seven out of eight studies on outpatients included patients with mildCOVID-19 defined according to the study protocols (WHO scale 2–3). Another small Phase 3 single-centre study …
R Zou, L Peng, D Shu, L Zhao, J Lan, G Tan… - Frontiers in …, 2022 - frontiersin.org
… with mild or moderate COVID-19. Patients were randomized to orally receive molnupiravir (… (primary endpoint) was significantly decreased in the molnupiravir group (median, 9 days) …
F Tian, Q Feng, Z Chen - International Journal of Antimicrobial Agents, 2023 - Elsevier
… has been approved for import registration for the treatment of mild-to-moderate COVID-19 patients with advanced severe high-risk factors, such as advanced age, obesity or overweight, …